Highlights
- Fortis Healthcare has maintained its long-term EBITDA margin target for FY28.
- The company plans to add 400 beds during FY27 through cluster-focused expansion.
- A ₹252 crore investment has been approved for a Proton therapy facility in Gurugram.
- Q1 FY27 revenue increased compared with the previous year.
- Agilus Diagnostics continues to focus on growth and margin improvement.
Fortis Healthcare Outlines Growth and Expansion Strategy
Fortis Healthcare Limited has reiterated its long-term operational roadmap, including a target of achieving a 25% EBITDA margin by FY28. The company outlined its strategy during its Q1 FY27 earnings discussion, focusing on hospital capacity expansion, operational improvement and investments in specialised healthcare services.
The company plans to expand its hospital network through a cluster-focused approach, adding capacity in existing markets. Alongside hospital expansion, Fortis is investing in advanced treatment infrastructure through its planned Proton therapy facility in Gurugram.
Q1 FY27 Financial Performance
Fortis Healthcare reported consolidated revenue of ₹2,545 crore in Q1 FY27, compared with ₹2,167 crore in Q1 FY26, representing a 17.5% YoY increase.
Operating Earnings Before Interest, Tax, Depreciation and Amortisation (EBITDA) stood at ₹568 crore during the quarter compared with ₹491 crore in the previous corresponding period.
The hospital business contributed to the quarterly performance, with revenue increasing 19% YoY to ₹2,187 crore from ₹1,838 crore in Q1 FY26.
Hospital Capacity Expansion Plans
Fortis Healthcare plans to add 400 beds during the remaining nine months of FY27. The expansion includes approximately 200 beds from the Fortis Memorial Research Institute (FMRI) facility.
The company’s expansion strategy focuses on increasing capacity within existing healthcare clusters, including major urban markets. The approach is aimed at improving operational utilisation while building additional healthcare capacity.
New bed additions require a ramp-up period before reaching mature operating levels, making occupancy and operational management important factors.
₹252 Crore Proton Therapy Facility Investment
The company’s board has approved capital expenditure of ₹252 crore for establishing a Proton therapy oncology facility at its Gurugram hospital.
The facility is expected to expand Fortis Healthcare’s specialised oncology treatment capabilities. Proton therapy is an advanced radiation treatment technology used in certain cancer care applications.
The investment forms part of the company’s broader focus on adding specialised healthcare services.
Agilus Diagnostics Growth Outlook
Fortis Healthcare’s diagnostics business, Agilus Diagnostics, continues to focus on revenue growth and margin performance. The division is targeting 12-13% revenue growth and EBITDA margins of 24-25% during FY27.
Diagnostics remains an important part of the healthcare services ecosystem, with demand influenced by preventive healthcare trends, medical testing requirements and service expansion.
Healthcare Industry Environment
The Indian healthcare sector continues to see demand for additional hospital capacity, specialised treatments and diagnostic services. Factors such as healthcare awareness, insurance coverage and urban healthcare requirements influence sector growth.
Hospital operators also need to manage costs, regulatory requirements, workforce availability and the operational ramp-up of new facilities.
Key Risks and Challenges
Fortis Healthcare faces risks related to the ramp-up of newly added beds, operating costs associated with expansion and changes in healthcare regulations. New facilities may require time to achieve targeted utilisation levels. The company’s margins may also be affected by employee-related costs, pricing changes and regulatory developments affecting hospital and diagnostic services.
Outlook
Fortis Healthcare continues to focus on capacity expansion, operational improvement and specialised healthcare investments. The company reported Q1 FY27 consolidated revenue of ₹2,545 crore and operating EBITDA of ₹568 crore. Management has maintained its target of achieving a 25% EBITDA margin by FY28 while planning to add 400 beds during FY27. The approved ₹252 crore Proton therapy facility investment and the diagnostics business growth plan are key parts of the company’s expansion strategy. Future performance will depend on occupancy levels, new facility ramp-up, cost management and healthcare demand trends.
Conclusion
Fortis Healthcare’s FY27 roadmap combines hospital capacity expansion, specialised treatment investments and operational improvement initiatives. The company’s Q1 FY27 results showed higher revenue and EBITDA compared with the previous year, while planned investments aim to support future healthcare service capabilities. Execution of bed additions, utilisation improvement and management of operating costs will remain important factors influencing the company’s progress.
FAQs
Q: What EBITDA margin target has Fortis Healthcare set for FY28?
A: Fortis Healthcare has maintained its target of achieving a 25% EBITDA margin by FY28.
Q: How many beds does Fortis Healthcare plan to add in FY27?
A: The company plans to add 400 beds during the remaining nine months of FY27.
Q: What is the planned investment in Fortis Healthcare’s Proton therapy facility?
A: Fortis Healthcare has approved capital expenditure of ₹252 crore for a Proton therapy facility at its Gurugram hospital.
Q: What was Fortis Healthcare’s Q1 FY27 revenue?
A: Fortis Healthcare reported consolidated revenue of ₹2,545 crore in Q1 FY27.
Q: What is the growth outlook for Agilus Diagnostics?
A: Agilus Diagnostics is targeting 12-13% revenue growth and EBITDA margins of 24-25% during FY27.